DBV Technologies S.A. - American Depositary Shares (DBVT)

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.

U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. S&P 500, Dow, Nasdaq 100 & R2K were down.

DBV Technologies progresses with regulatory efforts for its Viaskin Peanut patch in the U.S. and Europe, while financial concerns loom as the company seeks additional funding to continue its operations.

DBVT stock results show that DBV Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

DBVT stock results show that DBV Technologies beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.